1-3 of 3
Yan Ji
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 851–859.
https://doi.org/10.1158/1078-0432.CCR-21-3032
Published: 01 March 2022
View article titled, Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Open the PDF for Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

Komal Jhaveri, Dejan Juric, Yoon-Sim Yap, Sara Cresta, Rachel M. Layman, Francois P. Duhoux, Catherine Terret, Shunji Takahashi, Jens Huober, Nicole Kundamal, Qing Sheng, Alejandro Balbin, Yan Ji, Wei He, Adam Crystal, Serena De Vita, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5760–5770.
https://doi.org/10.1158/1078-0432.CCR-21-1095
Published: 01 November 2021
View article titled, A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Open the PDF for A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice

Whitney Banach-Petrosky, Xuesong Ouyang, Hui Gao, Kamyar Nader, Yan Ji, Nanjoo Suh, Robert S. DiPaola, Cory Abate-Shen
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5895–5901.
https://doi.org/10.1158/1078-0432.CCR-06-1039
Published: 04 October 2006
View article titled, Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in <em>Nkx3.1; Pten</em> Mutant Mice
Open the PDF for Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in <em>Nkx3.1; Pten</em> Mutant Mice in another window